Clinical Trial Update: Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating niraparib in combination with pembrolizumab in triple-negative breast cancer and ovarian cancer has been completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Niraparib (Niraparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Neoplasms, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-11